| Primary |
| Metastases To Bone |
14.6% |
| Breast Cancer |
12.0% |
| Osteoporosis Postmenopausal |
11.1% |
| Osteoporosis |
10.1% |
| Prostate Cancer |
9.8% |
| Hypertension |
8.6% |
| Bone Giant Cell Tumour |
4.5% |
| Constipation |
4.5% |
| Nausea |
4.1% |
| Diabetes Mellitus |
3.0% |
| Product Used For Unknown Indication |
2.9% |
| Prophylaxis |
2.7% |
| Pain |
2.1% |
| Back Pain |
1.7% |
| Supplementation Therapy |
1.7% |
| Hypercalcaemia Of Malignancy |
1.6% |
| Bone Density Decreased |
1.3% |
| Hyperlipidaemia |
1.3% |
| Infection |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
|
| Osteonecrosis Of Jaw |
36.5% |
| Osteomyelitis |
7.5% |
| Osteonecrosis |
7.3% |
| Pain In Jaw |
5.8% |
| Death |
5.6% |
| Exposed Bone In Jaw |
3.4% |
| Pulmonary Embolism |
3.4% |
| Cerebrovascular Accident |
3.2% |
| Pneumothorax |
2.9% |
| Alveolar Osteitis |
2.7% |
| Osteoarthritis |
2.7% |
| Back Pain |
2.4% |
| Neutropenia |
2.4% |
| Periodontal Disease |
2.4% |
| Vomiting |
2.2% |
| Femur Fracture |
1.9% |
| Hypocalcaemia |
1.9% |
| Pyrexia |
1.9% |
| Spinal Compression Fracture |
1.9% |
| Cellulitis |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
21.2% |
| Metastases To Bone |
18.8% |
| Osteoporosis |
13.3% |
| Breast Cancer |
5.9% |
| Breast Cancer Metastatic |
3.9% |
| Decreased Appetite |
3.5% |
| Hypertension |
3.5% |
| Rheumatoid Arthritis |
3.5% |
| Cancer Pain |
3.1% |
| Prostate Cancer |
3.1% |
| Bone Giant Cell Tumour |
2.7% |
| Mineral Supplementation |
2.7% |
| Prophylaxis |
2.4% |
| Prostate Cancer Metastatic |
2.4% |
| Gastrooesophageal Reflux Disease |
2.0% |
| Pain |
2.0% |
| Cerebrovascular Accident |
1.6% |
| Diabetes Mellitus |
1.6% |
| Sarcoidosis |
1.6% |
| Bone Disorder |
1.2% |
|
| Osteonecrosis Of Jaw |
35.5% |
| Pneumothorax |
11.3% |
| Blood Parathyroid Hormone Increased |
4.8% |
| Burning Sensation |
4.8% |
| Colonic Polyp |
4.8% |
| B-cell Lymphoma |
3.2% |
| Fatigue |
3.2% |
| Haematuria |
3.2% |
| Malaise |
3.2% |
| Potentiating Drug Interaction |
3.2% |
| Pyrexia |
3.2% |
| Rhabdomyolysis |
3.2% |
| Tachycardia |
3.2% |
| Tongue Disorder |
3.2% |
| Acute Hepatic Failure |
1.6% |
| Anaemia |
1.6% |
| Atrial Fibrillation |
1.6% |
| Back Pain |
1.6% |
| Cerebral Infarction |
1.6% |
| Cholecystitis Acute |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.7% |
| Metastases To Bone |
6.2% |
| Pain |
6.1% |
| Prostate Cancer |
5.6% |
| Prophylaxis |
5.5% |
| Supplementation Therapy |
5.3% |
| Prostate Cancer Metastatic |
4.5% |
| Constipation |
4.2% |
| Breast Cancer Metastatic |
4.0% |
| Hypertension |
3.8% |
| Nausea |
3.5% |
| Breast Cancer |
3.3% |
| Premedication |
3.2% |
| Non-small Cell Lung Cancer |
3.0% |
| Cough |
2.4% |
| Vitamin Supplementation |
2.3% |
| Rheumatoid Arthritis |
1.9% |
| Back Pain |
1.8% |
| Dyspnoea |
1.8% |
| Insomnia |
1.8% |
|
| Death |
8.7% |
| Thrombocytopenia |
8.7% |
| Weight Decreased |
8.7% |
| Prostate Cancer |
7.2% |
| Renal Failure |
7.2% |
| Vomiting |
7.2% |
| Deep Vein Thrombosis |
4.3% |
| Disease Progression |
4.3% |
| Interstitial Lung Disease |
4.3% |
| Myocardial Infarction |
4.3% |
| Nausea |
4.3% |
| Pneumonia |
4.3% |
| Pyrexia |
4.3% |
| Sepsis |
4.3% |
| Asthenia |
2.9% |
| C-reactive Protein Decreased |
2.9% |
| Cardiac Failure Congestive |
2.9% |
| Dyspnoea |
2.9% |
| Febrile Neutropenia |
2.9% |
| General Physical Health Deterioration |
2.9% |
|
